Additional file 14 of Potentiation of cord blood cell therapy with erythropoietin for children with CP: a 2 × 2 factorial randomized placebo-controlled trial
posted on 2020-11-28, 04:48authored byKyunghoon Min, Mi Ri Suh, Kye Hee Cho, Wookyung Park, Myung Seo Kang, Su Jin Jang, Sang Heum Kim, Seonkyeong Rhie, Jee In Choi, Hyun-Jin Kim, Kwang Yul Cha, MinYoung Kim
Additional file 14.Subgroup comparisons of GMPM change ratios among 4 groups. Legends: Panel A shows subgroup analyses using GMPM change ratios according to (a) severe (GMFCS levels IV and V) vs. (b) mild (GMFCS levels I to III) impairment while Panel B shows GMPM change ratios according to (a) preterm (GA < 37 weeks) vs. (b) term (GA ≥ 37 weeks) birth. Among severely impaired subjects (n = 55, A: 14, B: 15, C: 10, D: 16), group A showed a larger improvement in the GMPM change ratio at 1 month and 12 months post-treatment than group D (P = 0.028 and P = 0.008, respectively) (Panel A-(a)). In term birth subgroup (n = 23, A: 6, B: 4, C: 4, D: 9), groups A and B showed significant improvement in the GMPM change ratio at 1, 6 month and 12 months post-treatment compared to groups C and D (P = 0.003, P = 0.029 and P = 0.011, respectively) (Panel B-(b)). Abbreviations: CP, cerebral palsy; EPO, erythropoietin; GA, gestational age; GMFCS, gross motor function classification system; UCB, umbilical cord blood.
Funding
Health Promotion Administration, Ministry of Health and Welfare